semaglutide therapy des moines New Leaf Wellness - GLP-1 in West Moines, IA 🧠✨ The Modern Medicine Symposium

KanekoSHiraiKMorinoJMinatoSYanaiKMutsuyoshiYet alAssociation between carnitine deficiency and the erythropoietin resistance index in patients undergoing peritoneal dialysis: A cross-sectional observational study

To view or add a comment, sign in FDA grants traditional approval to Novartis' Fabhalta (Iptacopan), an an oral Factor B inhibitor to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) recognised as one of the most common autoimmune kidney diseases, with roughly 25 newly diagnosed cases per million people annually worldwide This first-in-class complement inhibitor received the approval through a priority review process after its initial accelerated approval in August 2024 for reducing proteinuria in primary IgAN To view or add a comment, sign in One in five people in the UK have fatty liver disease

For researchers following the broader GLP-1 therapy landscape and monitoring developments in peptides for fat loss and fat-burning peptide protocols , the next several years will bring even more options

While Jrgensens LinkedIn farewell post was gracious and forward-looking, the underlying message is clear: the economic model surrounding GLP-1s is under pressure, and providers must prepare for clinical and market volatility

Researchers are also studying an injectable version, which is further along in the clinical development process

Intravenous, intramuscular, and nebulized routes achieve higher systemic levels but require clinical administration and are reserved for specific medical indications